Solventum Corporation (NYSE:SOLV) Stock Has Average Target Price of $92.80 According to Analysts

Key Points

• Analysts generally favor Solventum: Fourteen firms give the stock a consensus “Moderate Buy” rating, with 10 buys, three holds and one sell. The average 12-month price target is $92.80, above the reported opening price of $86.70.
• Solventum recently exceeded earnings expectations, reporting $2.55 in quarterly EPS versus the $1.91 consensus and revenue of $2.21 billion. Revenue increased 2.2% year over year, while the company issued fiscal 2026 EPS guidance of $7.10–$7.20.
• The stock has traded between $62.38 and $94.16 over the past year and has a market capitalization of approximately $14.76 billion. Several institutional investors recently increased their positions in SOLV.

Shares of Solventum Corporation (NYSE:SOLV - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fourteen research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $92.80.

Several research analysts recently issued reports on the company. Wall Street Zen raised Solventum from a "hold" rating to a "buy" rating in a research report on Saturday, September 12th. Piper Sandler increased their price target on Solventum from $92.00 to $105.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. BTIG Research restated a "buy" rating and set a $95.00 price objective on shares of Solventum in a research note on Monday, September 14th. KeyCorp lifted their price objective on shares of Solventum from $93.00 to $102.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Finally, Weiss Ratings raised shares of Solventum from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, August 18th.

Solventum Price Performance

Shares of SOLV opened at $86.70 on Thursday. The stock has a market cap of $14.76 billion, a P/E ratio of 10.60, a P/E/G ratio of 1.33 and a beta of 0.63. The business's fifty day moving average is $88.70 and its 200 day moving average is $80.47. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. Solventum has a 12-month low of $62.38 and a 12-month high of $94.16.

Solventum (NYSE:SOLV - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, topping analysts' consensus estimates of $1.91 by $0.64. The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The firm's revenue was up 2.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Sell-side analysts anticipate that Solventum will post 7.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SOLV. IFP Advisors Inc grew its position in Solventum by 12.7% in the 3rd quarter. IFP Advisors Inc now owns 1,211 shares of the company's stock worth $107,000 after purchasing an additional 136 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of Solventum by 2.2% during the 1st quarter. NewEdge Advisors LLC now owns 6,707 shares of the company's stock worth $438,000 after buying an additional 144 shares in the last quarter. HB Wealth Management LLC lifted its position in shares of Solventum by 3.5% during the 1st quarter. HB Wealth Management LLC now owns 4,292 shares of the company's stock worth $280,000 after buying an additional 147 shares in the last quarter. Clearstead Trust LLC boosted its stake in shares of Solventum by 61.0% in the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company's stock worth $26,000 after buying an additional 150 shares during the last quarter. Finally, Diversify Advisory Services LLC boosted its stake in shares of Solventum by 3.2% in the 3rd quarter. Diversify Advisory Services LLC now owns 5,000 shares of the company's stock worth $439,000 after buying an additional 153 shares during the last quarter.

Solventum Company Profile

Solventum Corporation NYSE: SOLV is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company's portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.